Loading clinical trials...
Loading clinical trials...
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Conditions
Interventions
Lanreotide (Autogel formulation)
Placebo
+1 more
Locations
57
United States
Arizona Oncology Associates
Tucson, Arizona, United States
VA Greater Los Angeles
Los Angeles, California, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
Ochsner Medical Center
New Orleans, Louisiana, United States
Dana-Farber Institute
Boston, Massachusetts, United States
Karmanos Cancer Center
Detroit, Michigan, United States
Start Date
March 6, 2017
Primary Completion Date
February 28, 2020
Completion Date
February 28, 2020
Last Updated
July 6, 2022
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions